Potassium Iodide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Potassium Iodide: From Thyroid/Antimicrobial Use to Nasal Cavity Disease
One-Sentence Summary
Potassium Iodide (DrugBank DB06715) has no original indication recorded in this evidence pack, and detailed mechanism-of-action data is currently unavailable — pharmacologically it is a halide salt long used for thyroid-related and antimicrobial purposes. The TxGNN model predicts it may be effective for Nasal Cavity Disease, but this is currently supported only by 0 clinical trials and 4 case-report publications (mostly veterinary), with no controlled human studies.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the regulatory data provided (see “Why is This Prediction Reasonable?” below) |
| Predicted New Indication | Nasal Cavity Disease |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L4 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for potassium iodide in this evidence pack (flagged as a High-severity data gap, DG002). No original indication is registered either — the regulatory record shows 0 licenses and the drug is not currently marketed.
Based on the literature evidence retrieved, potassium iodide (KI) has a long, informal history as an adjunct antimicrobial/antifungal agent for so-called “sporotrichoid” mycotic infections — conditions such as pythiosis, aspergillosis, pseudallescheriasis and zygomycosis that can present as nasal or facial masses. The four supporting publications describe KI used successfully (or as an adjunct) in exactly this pattern of disease, which is consistent with the predicted “nasal cavity disease” indication.
However, three of the four publications are veterinary case reports (sheep, horse) and the fourth is a single decades-old human case report. The exact molecular mechanism behind KI’s antifungal/anti-inflammatory effect in these conditions remains unclear, and no controlled human trial has tested this use. The prediction should be read as a plausible historical/anecdotal signal rather than an established mechanistic link.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34902797 | 2022 | Case report (veterinary) | Journal de mycologie médicale | Successful potassium iodide treatment for rhinofacial pythiosis in sheep |
| 39576399 | 2024 | Case report (veterinary) | Veterinary Research Communications | Topical clotrimazole plus oral potassium iodide used to treat Aspergillus-related mycotic rhinitis in a horse |
| 10976304 | 2000 | Case report (veterinary) | Journal of the American Veterinary Medical Association | Sodium iodide (IV) used adjunctively with intranasal miconazole for Pseudallescheria boydii nasal cavity infection in a horse |
| 7997795 | 1994 | Case report | Revista do Instituto de Medicina Tropical de São Paulo | Rapid clinical response to potassium iodide therapy in a human case of nasofacial zygomycosis |
Australia Market Information
No ARTG entries are recorded for potassium iodide in this evidence pack (total licenses: 0; market status: not marketed).
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication is supported only by four case reports (three veterinary, one 30-year-old human report), with no clinical trials, no defined mechanism of action, and no current market presence in this jurisdiction (0 ARTG entries). Evidence is insufficient to progress beyond a research question at this stage.
To proceed, the following is needed:
- TFDA-approved Product Information (warnings/contraindications) to complete an initial safety assessment (currently blocking, DG001)
- Confirmed mechanism of action data from DrugBank or primary literature (DG002)
- At minimum, a systematic review or prospective case series in humans specifically for nasal cavity disease/sporotrichoid mycoses, rather than isolated case reports
- Clarification of dosage form and route feasibility for a nasal/sinus indication, since no ARTG-registered product currently exists
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.